Quemliclustat
As of the edition of 20 October 2026, Quemliclustat is a small molecule: in active development; acts on NT5E.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2030
- Kind
- Small molecule
- Registered trials
- 12, 0 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NT5E | 5'-nucleotidase | P21589 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 9 | 2 | 7 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Arcus Biosciences | Lead sponsor of trials | 2019 to now |
| Gilead Sciences | Lead sponsor of trials | 2023 to now |